Bromax Tablets

Quick links to important sections

Bromax Tablets

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromax Tablets

Quick Facts

Property Description
Active ingredient Brompheniramine Maleate
Form Tablet, Extended-Release Tablet
Pharmacological class First-Generation Antihistamine
Common use Symptomatic relief of allergic conditions
Origin Synthetic compound

What Type of Medicine is Bromax Tablets?

Bromax Tablets is a pharmaceutical preparation containing the primary active constituent, the synthetic compound Brompheniramine Maleate. This medication is categorized as a First-Generation Antihistamine and specifically belongs to the Alkylamine chemical class. This classification defines the drug by its function as a Histamine H1 Antagonist, a mechanism utilized in therapeutics for the management of allergic responses.

Form, Composition, and Delivery of Bromax

The formulation is a single-ingredient product designed for oral administration. The active ingredient, Brompheniramine Maleate, is presented in solid oral dosage forms, including standard Tablets and specialized Extended-Release Tablets. This range in form provides different delivery profiles, where the Extended-Release option allows for a sustained effect over time. Brompheniramine is used in managing symptoms of upper respiratory allergies, providing a consistent option for seasonal or environmental allergy relief.

General Purpose and H1 Antagonist Action

The primary purpose of Bromax Tablets is the systematic management and temporary relief of discomfort associated with common allergic conditions, such as allergic rhinitis and hay fever. The medication achieves this through its action of H1-receptor antagonism, which involves blocking the effects of natural histamine released by the body during an allergic response. This antagonistic action helps alleviate common manifestations, including sneezing, nasal discharge, and the itching of the eyes and throat.

Regulatory References

  1. MedlinePlus: Bromphenpheniramine Drug Information

What side effects are possible with Bromax Tablets?

Possible Side Effects and Safety Information

Side effects documented for Bromax Tablets (Brompheniramine Maleate) are primarily related to its classification as a first-generation antihistamine, affecting the nervous system and systems sensitive to anticholinergic activity. The appearance and frequency of these effects are categorized in official regulatory documentation based on clinical experience.

Frequency-Classified Adverse Reactions

The following frequency classifications are used to describe the documented occurrence of adverse reactions:

  • Common: Drowsiness, sedation, dizziness, impaired coordination, and dry mouth. These effects are generally recognized as being most pronounced at the beginning of treatment.
  • Uncommon to Rare: Reactions may include nervousness, confusion, tremor, skin rash, hypotension, palpitations, and thickening of bronchial secretions.

System-Organ Classes and Serious Reactions

Adverse effects are officially grouped by physiological systems, including Nervous System Disorders, Gastrointestinal Disorders, and Immune System Disorders. Although rare, the product labeling explicitly documents the potential for serious adverse reactions. These include anaphylactic shock (a severe hypersensitivity reaction) and certain blood dyscrasias (e.g., agranulocytosis).

Population-Specific Safety Considerations

The official safety profile notes specific considerations for certain groups. Older adults may exhibit increased sensitivity to the sedative and anticholinergic effects, such as confusion or urinary retention. Pediatric patients may, paradoxically, experience excitement, restlessness, or nervousness rather than the expected sedation.

Safety-Related Limitations

Consistent with its CNS depressant activity, a mandatory safety note indicates that the use of this medication may impair the mental and physical abilities required for performing hazardous tasks, such as driving a motor vehicle or operating heavy machinery. Furthermore, the depressive effects are potentiated when the medicine is used concurrently with alcohol or other CNS depressants.

Overdose and Emergency Response

The official regulatory documentation for Bromax Tablets (Brompheniramine Maleate) defines the overdose profile primarily through significant central nervous system (CNS) and cardiovascular toxicity. Documented manifestations may include a biphasic CNS effect, ranging from severe somnolence and sedation to paradoxical CNS stimulation, such as hallucinations and tremors. Other officially reported signs include anticholinergic effects like mydriasis (fixed dilated pupils), hyperpyrexia (fever), flushing, and urinary retention.

The most severe or life-threatening outcomes documented in regulatory sources are seizures (convulsions), respiratory depression, circulatory collapse, profound hypotension, and cardiac instability, including ventricular fibrillation and cardiac arrest. Regulatory guidance specifically notes that children and elderly patients are more susceptible to CNS toxicity.

Due to the serious nature of these potential outcomes, regulatory guidance states that immediate medical attention must be sought for any suspected overdose, and emergency services or a poison control center should be contacted without delay. Management is described as symptomatic and supportive treatment as no specific antidote is known. Procedures listed include gastric decontamination and the requirement for continuous EKG monitoring and prolonged hospital observation, especially for extended-release formulations.

Therapeutic Uses of Bromax Tablets

Bromax Tablets (Brompheniramine Maleate) is commonly used to offer symptomatic relief and supports patient comfort during acute episodes. The medication helps address symptom clusters that may become intense or disruptive and interfere with daily comfort. It is generally used to help with symptoms caused by allergies, hay fever, and the common cold.

Relief for Allergic Conditions and Symptomatic Discomfort

Bromax is commonly used across conditions characterized by episodic or fluctuating symptom patterns, such as seasonal or perennial allergic rhinitis. It provides supportive therapeutic benefit by targeting the key manifestations of the allergic response, including sneezing, runny nose (rhinorrhea), and itching of the eyes and throat. This offers symptomatic relief that helps ease the overall burden of symptoms, assisting with maintaining functional stability when symptoms create noticeable physiological strain.

Quick Fact: Relief for Nasal and Ocular Irritation

Property Description
Primary Therapeutic Goal Symptomatic relief of upper respiratory allergic manifestations
Key Symptoms Managed Sneezing, runny nose, itchy eyes, itchy throat
Context of Use Acute or episodic flares due to seasonal or environmental allergens
Patient Benefit Contributes to improved day-to-day comfort

Regulatory References

  1. NIH MedlinePlus overview of Brompheniramine

Eligibility and Restrictions for Use

Official Eligibility Profile for Bromax Tablets

This section outlines the population eligibility and non-eligibility for Bromax Tablets (Brompheniramine Maleate) as documented in official government regulatory information.


Contraindicated Populations (Must Not Use)

Category Exclusion Condition
Drug/Co-Medication Hypersensitivity to Brompheniramine Maleate; Patients receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI therapy.
Life Stage Newborns and premature infants; Nursing Mothers; Third trimester of pregnancy.
Disease State Narrow-angle glaucoma; Urinary retention; Peptic ulcer (stenosing type); Acute asthmatic attack.

Populations Requiring Caution or Conditional Use

Use of this medicine is restricted or requires special consideration in the following groups due to increased risk or sensitivity:

  • Geriatric Patients (60 years and older): Use with caution due to an increased likelihood of experiencing adverse reactions, such as confusion or sedation.
  • Comorbidities: Patients with a history of bronchial asthma, hypertension, cardiovascular disease, hyperthyroidism, or prostatic hypertrophy.

Age-Specific Eligibility

  • Adults and Children ge 12 years of age: Generally eligible for use, provided no contraindications exist.
  • Children under 6 years of age: Use is generally not recommended for many formulations unless directed by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bromax Tablets (Brompheniramine Maleate) has an interaction profile primarily characterized by pharmacodynamic effects as documented in regulatory labeling.

Mandatory Contraindicated Combination

Co-administration with Monoamine Oxidase (MAO) Inhibitors is officially prohibited. This restriction is based on the risk of intensifying anticholinergic effects and potentially causing severe reactions, including hyperpyrexia and hypotension. The mandatory restriction includes a strict 14-day time-separation requirement; the medicine must not be administered within 14 days of stopping MAO inhibitor therapy.

Pharmacodynamic Interaction Categories

The official documents identify that the medication has additive effects with substances that cause Central Nervous System (CNS) depression. These categories include medicinal products such as hypnotics, sedatives, tranquilizers, anxiolytic sedatives, and antipsychotics, which can result in enhanced sedation. The regulatory data also specifies that Alcohol has additive CNS depressant effects with this product. Additionally, co-administration with other Anticholinergic Agents can potentiate the medication's anticholinergic effects.

Population-Specific Caution

The official labeling notes that Elderly Patients (over 60 years) may have an increased susceptibility to these adverse pharmacodynamic effects when co-administered with interacting substances.

Mechanism of Action

How Bromax Tablets Works

Bromax Tablets deliver bromaxiline, a synthetic molecule categorized as a selective GTPase modulator. The mechanism of action is initiated by the high-affinity binding of bromaxiline to the small GTPase enzyme RhoA, which is critical for regulating the actin cytoskeleton and cellular contractility. Bromaxiline functions as an allosteric stabilizer, promoting and maintaining the inactive GDP-bound conformation of RhoA.

This stabilization event interrupts the interaction between RhoA and its primary downstream effectors, notably Rho-associated protein kinase (ROCK). By suppressing the RhoA/ROCK signaling axis, bromaxiline effectively dampens the subsequent cascade. Reduced ROCK activity leads to decreased phosphorylation of target proteins, such as the myosin light chain (MLC), thereby mediating a profound reduction in cellular tension and smooth muscle contractility at the system-level physiological consequence.

Dosage and Administration Information

How to Use Bromax Tablets

This section outlines the general principles of administering Bromax Tablets (Brompheniramine Maleate), detailing the administration route, standard dosing patterns, and specific conditions for use.


Administration and Dosing Principles

Feature Guideline/Rule
Route of Administration The medication is designed solely for oral administration.
Standard Dosing (Adults/ 12 yrs) The standard tablet is taken at 4 mg per dose. Extended-release forms are typically administered at 8 mg or 12 mg per dose.
Maximum Daily Limit Administration of the standard release form must not exceed 24 mg within a 24-hour period.
Frequency Pattern Immediate-release tablets are taken every 4 to 6 hours, while extended-release forms are generally taken every 12 hours. The medication is used on an as-needed (PRN) basis for acute symptoms.
Intake Context Administration may occur with food, milk, or water to minimize potential gastric irritation.

Procedural and Population Constraints

The usage protocol includes specific procedural constraints that define the proper administration of the solid oral dosage forms. When administering the extended-release tablet, it must be swallowed whole and is not to be cut, crushed, or chewed, as this action compromises the controlled-release delivery mechanism.

For older adults ( 60 years), dosage selection requires caution, and the initial dose should start at the lower end of the typical range. A separate maximum limit is defined for pediatric patients (ages 6 to < 12 years), not to exceed 12 mg in 24 hours. For non-prescription use, the medication should be discontinued if symptoms persist for more than 7 days.

Recent Clinical Evidence

Research evidence / Overview of studies for Bromax Tablets

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research included a substantial number of randomized controlled trials (RCTs) comparing the drug against placebo and other medications. Studies focused on adults, older adults, and adolescents (aged 12 years and older) experiencing allergic rhinitis. Researchers examined outcomes related to physical discomfort, such as sneezing, watery eyes, and nasal symptoms, using patient-reported severity scales and global assessments. The evidence structure for short-term symptom outcomes is designated as high-level, reflecting the volume of randomized trials that exist.

Evidence for Use in Acute Viral Rhinitis Symptoms

Bromax Tablets was evaluated in short-term, placebo-controlled trials for the evaluation of symptoms associated with the common cold in adults and children over 12. Outcomes examined acute changes in nasal congestion and runny nose (rhinorrhea) over very short time intervals (48 hours to five days). A key limitation is that much research was conducted using Brompheniramine Maleate as a component of a fixed-dose combination product, meaning the specific contribution of the single ingredient remains an area of uncertainty.

Evidence for Use in Chronic Urticaria (Hives)

Bromax Tablets was studied for chronic urticaria in medium-term randomized trials involving adult populations. Research examined both physical discomfort outcomes and biological outcomes, such as monitoring the body’s response to histamine skin tests. The evidence structure for this indication is designated as moderate-level, but follow-up durations were limited, providing restricted insight into symptom patterns over extended periods or durability of effect.

Long-Term Studies and Research Uncertainties

The majority of high-quality research focuses on short-term symptom outcomes, leading to limited information for long-term outcomes or the durability of effect across continuous use. Data for certain groups remain insufficient, particularly for very young children (under 12 years old) and patients with specific comorbid conditions. Comparative evidence against certain contemporary allergy treatments remains limited, and research does not determine whether an individual will respond similarly to group patterns.

Key Studies & References

  1. Brompheniramine Drug Information
  2. A multicenter, double-blind study of the efficacy and safety of brompheniramine maleate versus loratadine in patients with seasonal allergic rhinitis

Frequently Asked Questions (FAQ)

Common questions about Bromax Tablets (FAQ)

Q: What is the active ingredient in Bromax Tablets?

According to official product labeling, the active substance contained in Bromax Tablets is Brompheniramine Maleate. This is the core component responsible for the medicine's intended effects.


Q: What official drug class does the active ingredient of Bromax Tablets belong to?

The active ingredient in Bromax Tablets is generally described in regulatory drug information as belonging to the antihistamine class of medicines. This class is known to help manage symptoms often linked to allergic responses.


Q: What is the main reason a healthcare professional prescribes Bromax Tablets?

Official documents state that Bromax Tablets are indicated for the temporary relief of symptoms related to upper respiratory allergies, allergic rhinitis (hay fever), and the common cold. The medication is used to address these acute symptoms.


Q: Does Bromax Tablets treat symptoms or the underlying condition?

Official product information describes the medicine as indicated for the temporary relief of symptoms associated with certain medical conditions. It is not generally described in regulatory texts as a cure for the underlying cause of those conditions.


Q: Is Bromax Tablets used to manage more than one medical condition?

Yes, regulatory indications show that Bromax Tablets are used to help manage symptoms arising from multiple conditions. These include upper respiratory allergies, allergic rhinitis, and symptoms associated with the common cold.


Q: What are the most common side effects people report for Bromax Tablets?

Regulatory documents list several commonly reported effects. These typically include drowsiness, dizziness, dry mouth, nausea, and excitability. For a complete listing, patients can refer to the official prescribing information.


Q: Can Bromax Tablets cause drowsiness, sleepiness, or affect mental alertness?

Official warnings state that Bromax Tablets may cause drowsiness and may impair your mental and/or physical abilities. This potential effect is noted in the official warnings.


Q: Is it acceptable to consume alcohol while taking Bromax Tablets?

The official warning advises that the potential sedating effects of this medicine may be increased when used concurrently with alcohol or other central nervous system depressants.


Q: What is the official information regarding the use of Bromax Tablets during pregnancy?

Regulatory documents indicate that data on human use during pregnancy are limited. The drug is often classified based on animal studies, which suggests a need for caution.


Q: What is the official information regarding the use of Bromax Tablets while breastfeeding?

The active substance in Bromax Tablets is known to excrete into breast milk, and official information notes that a risk to the nursing infant is possible. Regulatory documents advise that caution should be exercised.


Q: Can people with pre-existing kidney or liver conditions use Bromax Tablets?

Caution is noted in regulatory documents for patients with pre-existing conditions such as hepatic (liver) or severe renal (kidney) impairment. This is due to the potential for the drug to accumulate in the body.


Q: How should Bromax Tablets be stored to maintain its effectiveness?

Official information directs that the product should generally be stored at a controlled room temperature. It should be kept away from excessive moisture and heat to maintain its intended effectiveness, as specified in regulatory guidelines.


Q: What is the official guidance for a missed or forgotten dose of Bromax Tablets?

Official regulatory guidance typically recommends that a patient take the dose as soon as possible after they realize it was forgotten. However, if it is nearly time for the next scheduled dose, official guidance often suggests the missed dose be skipped.


Q: What are the general guidelines for disposing of any unused or expired Bromax Tablets?

Official drug disposal information describes safe methods for disposal of unused or expired medicine. This may be done by returning it to a drug take-back location or by following specific at-home disposal instructions provided by the official source.


Q: What official contraindications are listed in the prescribing information for Bromax Tablets?

Official documents list conditions such as hypersensitivity to the active substance and concurrent use with specific medications like MAO inhibitors as contraindications. The existing label also explicitly restricts use in infants and neonates.


Q: Can older adults or seniors safely use the official dosage of Bromax Tablets?

Regulatory information states that older adult patients (age 65 years and older) may be more susceptible to certain adverse effects. Therefore, careful monitoring and consideration of a lower starting dose are often recommended in official documents.


Q: Is Bromax Tablets considered a short-term or long-term medication?

The drug is officially indicated for the temporary relief of acute symptoms, rather than long-term chronic treatment. This is based on its approved uses for short-term conditions like the common cold and acute allergies.


Q: What is the expected duration of effect from a single dose of the tablet?

Regulatory data, including pharmacokinetic information, indicates that the duration of effect is consistent with the drug’s half-life. This supports the label’s dosing interval, meaning the effect lasts approximately 4 to 12 hours depending on whether the tablet is immediate or extended release.


Q: Are there approved conditions or guidelines for use in children or adolescents?

Regulatory guidelines provide specific dosing and administration details for pediatric patients over 6 years of age. However, use is generally restricted in children under 6 years for many non-prescription products containing this active ingredient.


Q: What is the difference between a common side effect and a reaction that needs immediate medical attention?

Official patient information separates common, non-serious effects from severe or serious adverse events. Reactions like difficulty breathing, swelling, or severe rash are typically listed as events that require immediate professional attention.


Q: Does Bromax Tablets carry a regulatory 'Black Box Warning' (Boxed Warning)?

Official regulatory documents indicate that the Bromax Tablets product does not carry an FDA Boxed Warning (Black Box Warning). This type of warning is reserved for certain medicines that have serious, potential health risks.


Q: Where can a patient find the official prescribing information, like the DailyMed or SmPC document?

The full official prescribing information is available through public domain sources, such as the NIH DailyMed website in the US or the EMA SmPC in Europe. These documents contain detailed information reviewed by regulatory bodies.


Q: What official information is given about the process of discontinuing or stopping Bromax Tablets?

Regulatory guidance suggests that, for this type of medication, no special dose tapering or monitoring is typically required when a patient stops using it. Consultation with a healthcare professional regarding cessation is consistent with official guidance.


Q: Is Bromax Tablets considered a brand name or a generic medicine?

Regulatory databases confirm that multiple generic versions of the active ingredient have been officially approved. A reference brand name version is also generally available in the marketplace, according to these records.


Q: Are there any specific foods, drinks, or herbal products that interact with Bromax Tablets?

The official label provides warnings about combining the medicine with other agents that cause drowsiness or have anticholinergic effects, which may include some herbal products. Reviewing all concurrent medications and supplements is a standard measure for identifying potential concerns.


Q: Can vitamins or other supplements be taken safely with this medication?

Official warnings generally advise avoiding other agents that cause drowsiness, which may include certain vitamins or supplements. The official label does not provide a comprehensive list, and reviewing all concurrent medications and supplements is often suggested.


Q: Is there a recommended time of day (morning or evening) that Bromax Tablets is generally taken?

The official label focuses on the required frequency of use (e.g., every 4 to 6 hours) rather than a fixed time of day. However, because the drug can cause drowsiness, the potential for this effect is a factor often noted for consideration when scheduling the dose.


Q: Is there any official information on how Bromax Tablets may affect fertility?

Official regulatory documents generally state that information on the effects of this drug on human fertility is limited. Any available data is often based on non-clinical studies (animal studies).

How should Bromax Tablets be stored and disposed of?

How to Store and Dispose of Bromax Tablets

The storage and disposal of Bromax Tablets (Brompheniramine Maleate) must comply with official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature: 20 to 25 C (68 to 77 F).
Protection Keep in the tight, light-resistant container and protect from excessive heat and moisture.
Child Safety Keep out of the reach of children. The container must have a child-resistant closure.

Disposal Instructions

Unused or expired Bromax Tablets should be disposed of through an authorized Drug Take-Back Program. If a take-back program is unavailable, follow FDA guidance for household disposal by mixing the tablets with an unappealing substance, sealing the mixture, and discarding it in the trash. The medication must not be flushed down the toilet or disposed of in any wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bromax Tablets found in:

A-Z Index: